2. Search Result
Search Result
Results for "

oedema

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

3

Peptides

3

Inhibitory Antibodies

8

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0171A
    Beta-Sitosterol (purity>98%)
    15+ Cited Publications

    β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)

    		 Bacterial Apoptosis Reactive Oxygen Species (ROS) MDM-2/p53 Caspase PARP MMP Bcl-2 Family HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related NF-κB mTOR Lactate Dehydrogenase CDK Glutathione Peroxidase SOD Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc .
    Beta-Sitosterol (purity>98%)
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-N6028
    Darutoside
    1 Publications Verification

    		 COX NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis .
    Darutoside
  • HY-101432
    Fenclozic acid

    ICI-54450; Acidum fenclozicum; Mialex

    		 COX Inflammation/Immunology
    Fenclozic acid (ICI-54450) is an orally active anti-inflammatory, analgesic, and antipyretic agent. Fenclozic acid exhibits anti-inflammatory activity in Edadjuvant-induced arthritis and Carrageenin-induced oedema in rats. Fenclozic acid can be used for the research of arthritis .
    Fenclozic acid
  • HY-100845
    Salvinorin A

    Divinorin A

    		 Opioid Receptor Cardiovascular Disease
    Salvinorin A is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with Ki value of 4.3 nm. Salvinorin A is a non-nitrogenous neoclerodane isolated from Salvia divinorum.
    Salvinorin A
  • HY-N1205
    Spathulenol

    		Others Cancer
    Spathulenol is isolated from Aristolochia yunnanensis, and has antioxidant, anti-inflammatory, antiproliferative and antimycobacterial activities. Spathulenol shows a high antioxidant activity with an IC50 of 85.60 μg/mL in the DPPH system [1].
    Spathulenol
  • HY-U00153
    Dixyrazine

    		Drug Derivative Neurological Disease
    Dixyrazine, a phenothiazine derivative, can prevent brain oedema induced by intracarotid injection of protamine sulphate.
    Dixyrazine
  • HY-W050088
    Isoxepac

    HP 549

    		 Drug Derivative Neurological Disease Inflammation/Immunology
    Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
    Isoxepac
  • HY-110036
    GW-405833

    L768242

    		 Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values ​​of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values ​​of 16.1 μM and 4772 nM for CB1. GW-405833 also exhibits non-competitive CB1 antagonist, exerting its analgesic and and anti-inflammatory effect through a CB1 receptor (rather than CB2) dependent mechanism. GW-405833 can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .
    GW-405833
  • HY-W009706
    Alclofenac

    Allopydin; W-7320

    		 Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    Alclofenac (Allopydin) is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica .
    Alclofenac
  • HY-103025
    Methylprednisolone aceponate
    2 Publications Verification

    ZK 91588; MPA

    		 Glucocorticoid Receptor Inflammation/Immunology
    Methylprednisolone aceponate (ZK 91588) is a glucocorticoid and anti-inflammatory agent with weak systemic effects. Methylprednisolone aceponate is a selective glucocorticoid receptor Ligand.Methylprednisolone aceponate can be used for research of eczema and other inflammatory skin disorders .
    Methylprednisolone aceponate
  • HY-105172
    TT-232

    CAP-232; TLN-232

    		 Somatostatin Receptor Inflammation/Immunology Cancer
    TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .
    TT-232
  • HY-B1254
    Altizide

    Althiazide

    		 Others Cardiovascular Disease
    Altizide (Althiazide) is an orally active diuretic. Altizide can be used in studies of oedema and hypertension .
    Altizide
  • HY-A0235
    Antrafenine

    Stakane

    		 COX Neurological Disease
    Antrafenine (Stakane) is a non-narcotic analgesic. Antrafenine demonstrates central analgesic effects in acetic acid writhing test and mouse hot plate test experiments. Antrafenine significantly alleviates the pain of osteoarthritis. Antrafenine exhibits mild anti-inflammatory activity in a rat toe edema model. Antrafenine can be used in pain and anti-inflammatory research .
    Antrafenine
  • HY-123179
    Mefruside

    		Carbonic Anhydrase Cardiovascular Disease
    Mefruside is an orally active diuretic and has a mild hypotensive effect. Mefruside inhibits the synthesis of urea in an isolated rat liver perfusion model. Mefruside can be used in studies of oedema and hypertension .
    Mefruside
  • HY-14840A
    (R)-Phenylpiracetam

    MRZ 9547

    		 Dopamine Transporter Neurological Disease Inflammation/Immunology
    (R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (Ki: 14.8 μM; IC50: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .
    (R)-Phenylpiracetam
  • HY-P5875A
    P4pal10 TFA

    		Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
    P4pal10 TFA
  • HY-404056
    (R)-AZ8838

    		Protease Activated Receptor (PAR) Inflammation/Immunology
    (R)-AZ8838 is a competitive PAR2 antagonist with a pKi of  5.2 for human PAR2. (R)-AZ8838 exert anti-inflammatory effects in a rat model of PAR2 agonist-induced paw oedema .
    (R)-AZ8838
  • HY-P991415
    ASKG-712

    AM712

    		 VEGFR Tie Others
    ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
    ASKG-712
  • HY-15791
    FR173657

    FK-3657

    		 Bradykinin Receptor Inflammation/Immunology
    FR173657 is an orally active bradykinin B2 receptor antagonist (IC50: 0.56, 1.5, 2.9 nM for pig, rat, human B2 receptor respectively). FR173657 (p.o.) inhibits BK-induced bronchoconstriction in guinea-pigs (ED50: 0.075 mg/kg). FR173657 (p.o.) also inhibits Carrageenin-induced paw oedema in mice (ED50: 6.8 mg/kg). FR173657 can be used for research of inflammatory disease .
    FR173657
  • HY-N2196
    Ajugasterone C

    		Others Inflammation/Immunology
    Ajugasterone C is an ecdysteroid isolated from Leuzea carthamoides. Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to Carrageenan-induced inflammation in Sprague Dawley rats .
    Ajugasterone C
  • HY-128473
    Valeryl salicylate

    Valeroyl salicylate

    		 COX Inflammation/Immunology
    Valeryl salicylate is a potent and irreversible cyclooxygenase-1 (COX-1) inhibitor. Valeryl salicylate shows anti-inflammatory effect .
    Valeryl salicylate
  • HY-110036A
    GW405833 hydrochloride

    L768242 hydrochloride

    		 Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values ​​of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values ​​of 16.1 μM and 4772 nM for CB1. GW405833 hydrochloride also exhibits non-competitive CB1 antagonist, exerting its analgesic effect through a CB1 receptor (rather than CB2) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .
    GW405833 hydrochloride
  • HY-105215
    FK888

    		Neurokinin Receptor Inflammation/Immunology
    FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
    FK888
  • HY-W995241
    BPD

    		COX NF-κB Inflammation/Immunology
    BPD is a COX-2 and TAK1-NF-κB inhibitor, with an IC50 of 18.5 μM for COX-2. BPD inhibits the expression of iNOS, TNF-α, IL-6 and IL-1β at the transcriptional level. BPD has anti-inflammatory activity. BPD can inhibit Carrageenan-induced paw oedema and LPS-induced septic death .
    BPD
  • HY-141622
    SDZ 224-015

    		Interleukin Related Caspase SARS-CoV Infection Inflammation/Immunology
    SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting M pro (IC50 of 30 nM) .
    SDZ 224-015
  • HY-126179
    Fenquizone

    MG-13054

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Fenquizone (MG-13054) is an orally active diuretic. Fenquizone acts primarily on the diluting segment of the nephron cortex, similar to thiazide diuretics. Fenquizone demonstrates diuretic and natriuretic potency and duration of action comparable to thiazide diuretics but weaker than loop diuretics.​ Fenquizone reduces CH₂O without affecting TCH₂O, does not increase calcium/phosphate excretion, and has no loop or collecting duct effects. Fenquizone is used in the study of edema and hypertension .
    Fenquizone
  • HY-W050088S
    Isoxepac-d6

    HP 549-d6

    		 Isotope-Labeled Compounds Drug Derivative Neurological Disease Inflammation/Immunology
    Isoxepac-d6 (HP 549-d6) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
    Isoxepac-d6
  • HY-P991416
    BAT5906

    		VEGFR Others
    BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
    BAT5906
  • HY-P991385
    UBX2050

    		Tie Neurological Disease Metabolic Disease
    UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
    UBX2050
  • HY-N10226
    Thielavin B

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin B is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin B effectively influences the prostaglandin E2 synthesis from the endoperoxide. Thielavin B is significantly effective on carrageenan-induced oedema of rats when administered intravenously .
    Thielavin B
  • HY-P5875
    P4pal10

    		Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
    P4pal10
  • HY-14886
    Fasitibant chloride

    MEN16132 free base

    		 Bradykinin Receptor Cardiovascular Disease Neurological Disease
    Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model .
    Fasitibant chloride
  • HY-105424
    Florifenine

    		COX Inflammation/Immunology
    Florifenine is a selective cyclooxygenase (COX) inhibitor with anti-inflammatory activity. Florifenine inhibits TXB2 in human whole blood with an IC50 of 32.5 nM. Florifenine exhibits anti-inflammatory effects in ear oedema. Florifenine inhibits neutrophil migration and reduces PGE2 levles in the inflamed ears. Florifenine inhibits leukocyte migration and PGE2 levels in the air pouch inflammation induced by Zymosan (HY-159069). Florifenine can be used for anti-inflammatory research .
    Florifenine
  • HY-111164
    CBS-3595

    		p38 MAPK Phosphodiesterase (PDE) Inflammation/Immunology
    CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808)-induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases .
    CBS-3595
  • HY-U00153R
    Dixyrazine (Standard)

    		Drug Derivative Reference Standards Neurological Disease
    Dixyrazine (Standard) is the analytical standard of Dixyrazine. This product is intended for research and analytical applications. Dixyrazine, a phenothiazine derivative, can prevent brain oedema induced by intracarotid injection of protamine sulphate.
    Dixyrazine (Standard)
  • HY-133173
    Niravoline

    RU51599

    		 Vasopressin Receptor Opioid Receptor Neurological Disease
    Niravoline (RU51599) is an arginine vasopressin (AVP) release inhibitor and a selective kappa opioid receptor agonist. Niravoline has a pure water diuresis effect without associated electrolyte excretion. Niravoline can reduce brain oedema following transient forebrain ischaemia in rats .
    Niravoline
  • HY-148925
    α-Amyrenone

    		Glycosidase Inflammation/Immunology
    α-Amyrenone is a triterpenoid that occurs naturally in very low concentrations in several oleoresins from Brazilian Amazon species of Protium (Burseraceae). The mixture of α and β-amyrenone inhibits α-glucosidase, and can reduce mechanical hypersensitivity and paw-oedema induced by carrageenan .
    α-Amyrenone
  • HY-137920
    Salvinorin A propionate

    		Opioid Receptor Cardiovascular Disease
    Salvinorin A (Divinorin A) propionate is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with Ki value of 4.3 nm. Salvinorin A propionate is a non-nitrogenous neoclerodane isolated from Salvia divinorum .
    Salvinorin A propionate
  • HY-121678
    Tetridamine

    POLI-67

    		 Biochemical Assay Reagents Inflammation/Immunology
    Tetridamine ((POLI-67) ) is a non-steroidal anti-inflammatory agent and shows a marked reduction of paw swelling and pain sensibility .
    Tetridamine
  • HY-103025R
    Methylprednisolone aceponate (Standard)

    ZK 91588 (Standard); MPA (Standard)

    		 Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Methylprednisolone aceponate (Standard) is the analytical standard of Methylprednisolone aceponate. This product is intended for research and analytical applications. Methylprednisolone aceponate (ZK 91588) is a glucocorticoid and anti-inflammatory agent with weak systemic effects. Methylprednisolone aceponate is a selective glucocorticoid receptor Ligand.Methylprednisolone aceponate can be used for research of eczema and other inflammatory skin disorders .
    Methylprednisolone aceponate (Standard)
  • HY-B1254A
    (-)-Altizide

    (-)-Althiazide

    		 Drug Isomer Cardiovascular Disease
    (-)-Altizide is the levorotatory enantiomer of Altizide (HY-B1254). Altizide is an orally active diuretic. Altizide can be used in studies of oedema and hypertension .
    (-)-Altizide
  • HY-N17743
    Deltoin

    		Drug Derivative NO Synthase Inflammation/Immunology
    Deltoin is a Coumarine derivative. Deltoin can be isolated from Seseli resinosum. Deltoin shows inhibitory activity on NO. Deltoin causes a significant inhibition against paw oedema. Deltoin shows anti-inflammatory activity .
    Deltoin
  • HY-126179R
    Fenquizone (Standard)

    MG-13054 (Standard)

    		 Reference Standards Potassium Channel Cardiovascular Disease Metabolic Disease
    Fenquizone (MG-13054) (Standard) is the analytical standard of Fenquizone (HY-126179). This product is intended for research and analytical applications. Fenquizone is an orally active diuretic. Fenquizone acts primarily on the diluting segment of the nephron cortex, similar to thiazide diuretics. Fenquizone demonstrates diuretic and natriuretic potency and duration of action comparable to thiazide diuretics but weaker than loop diuretics.​ Fenquizone reduces CH₂O without affecting TCH₂O, does not increase calcium/phosphate excretion, and has no loop or collecting duct effects. Fenquizone is used in the study of edema and hypertension.
    Fenquizone (Standard)
  • HY-W050088R
    Isoxepac (Standard)

    HP 549 (Standard)

    		 Reference Standards Drug Derivative Neurological Disease Inflammation/Immunology
    Isoxepac (Standard) (HP 549 (Standard)) is the analytical standard of Isoxepac (HY-W050088). This product is intended for research and analytical applications. Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .
    Isoxepac (Standard)
  • HY-119167
    Lotifazole

    F 1686

    		 COX Inflammation/Immunology
    Lotifazole (F 1686) is a non-steroidal anti-inflammatory agent. Lotifazole exhibits specific inhibition of delayed-type hypersensitivity and does not rely on the prostaglandin synthesis inhibition pathway at low doses. Lotifazole shows significant efficacy in treating paw edema induced by carrageenan in rats, erythema induced by ultraviolet radiation in guinea pigs, and pleurisy at high doses. Lotifazole can be used for the study of T-cell-mediated diseases .
    Lotifazole

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: